AIDS group seeks Trizivir withdrawal
Executive Summary
AIDS Healthcare Foundation asks FDA to withdraw approval of GlaxoSmithKline's HIV combination therapy Trizivir (abacavir/lamivudine/zidovudine) based on results from an NIH study reported in March. The study compared patients taking Trizivir alone to patients on Trizivir plus Bristol-Myers Squibb's Sustiva and patients on Sustiva and GSK's Combivir. NIH suspended the Trizivir-only arm after patients in that arm "experienced virologic failure...sooner and more often than patients in the other two arms of the study." GSK warned against use of its Ziagen (abacavir) and Epivir (lamivudine) in combination with Gilead's Viread (tenofovir) in a recent "Dear Doctor" letter (1"The Pink Sheet" Aug. 4, 2003, In Brief)...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.